Nitronazine by Guangzhou Magpie Pharmaceutical for Amyotrophic Lateral Sclerosis: Likelihood of Approval

Nitronazine is under clinical development by Guangzhou Magpie Pharmaceutical and currently in Phase II for Amyotrophic Lateral Sclerosis.

Kadans Science Partner commences work on new purpose-built wet lab facilities at Merlin Place, North Cambridge

Kadans Science Partner, a leading investor in the development of ecosystems and real estate with a dedicated focus on knowledge-intensive sectors, today announced that construction

July 24, 2024

Subsidiaries of Vita 34 reach agreement with US licensor – Biotech Investments

Vita 34 AG / Key word(s): Agreement/Scheme of Arrangement Subsidiaries of Vita 34 reach agreement with US licensor 09-Aug-2024 / 17:04 CET/CEST Disclosure of an

August 10, 2024

Zen and Psychedelics Documentary Follows Monks on Mushrooms

“The only Zen you find on tops of mountains is the Zen you bring there,” wrote author Robert M. Pirsig in his timeless novel Zen

September 27, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.